Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature

Axel de Bernardi; Thomas Bachelot; Louis Larrouquère

doi:10.3389/fonc.2023.1210873

Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature

Front Oncol. 2024 Jan 10:13:1210873. doi: 10.3389/fonc.2023.1210873. eCollection 2023.

Authors

Axel de Bernardi¹, Thomas Bachelot^{1

2}, Louis Larrouquère^{1

2}

Affiliations

¹ Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
² Cancer Reseach Center of Lyon, Lyon, France.

Abstract

The incidence of leptomeningeal metastases (LM) is increasing among breast cancer patients, but their prognosis remains dismal. Many therapeutic options are now available to treat HER2-positive (HER2+) metastatic breast cancer (MBC) involving the central nervous system (CNS). This case report illustrates a long-lasting response of more than 2 years in a patient with HER2+ MBC with LM after sequential administration of systemic and intrathecal (IT) anti-HER2 therapies and highlights that an appropriate treatment of HER2+ LM can result in durable survival.

Keywords: HER2; breast cancer; leptomeningeal metastasis; trastuzumab-deruxtecan; tucatinib.

Publication types

Review